CLDX · XBRL financial data
Celldex Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CLDX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 7 | 5 | 2 | 7 | 7 | 2 |
| Cost of goods and services sold | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 43 | 53 | 82 | 118 | 164 | 245 |
| General and administrative | 14 | 20 | 27 | 31 | 39 | 44 |
| Operating income (loss) | (63) | (71) | (115) | (155) | (195) | (287) |
| Income tax expense (benefit) | (1) | (0) | — | 0 | 0 | 0 |
| Net income (loss) | — | — | — | (141) | (158) | (259) |
| Earnings per share, basic USD per share | (2.02) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| Earnings per share, diluted USD per share | (2.02) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| Weighted average shares, basic millions of shares | 0 | 0 | 0 | 0 | 0 | 66 |
| Weighted average shares, diluted millions of shares | 0 | 0 | 0 | 0 | 0 | 66 |
Balance sheet
CSVFiscal years (CLDX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 44 | 39 | 29 | 35 | 28 | 29 |
| Marketable securities | 151 | 369 | 276 | 389 | 697 | 490 |
| Prepaid and other current assets | 2 | 2 | 12 | 5 | 21 | 14 |
| Total current assets | 198 | 411 | 318 | 432 | 747 | 535 |
| Property and equipment, net | 4 | 4 | 4 | 4 | 4 | 5 |
| Right-of-use asset | 3 | 3 | 4 | 3 | 4 | 2 |
| Total assets | 236 | 445 | 353 | 466 | 792 | 583 |
| Accounts payable | 1 | 1 | 3 | 3 | 3 | 1 |
| Accrued liabilities | 8 | 12 | 13 | 22 | 34 | 47 |
| Total current liabilities | 14 | 17 | 19 | 31 | 40 | 51 |
| Lease liability, non-current | 2 | 1 | 3 | 1 | 2 | 1 |
| Total liabilities | 26 | 25 | 27 | 36 | 45 | 56 |
| Accumulated deficit | (1,073) | (1,144) | (1,256) | (1,397) | (1,555) | (1,814) |
| Total stockholders' equity | 209 | 419 | 326 | 429 | 747 | 527 |
| Total liabilities and equity | 236 | 445 | 353 | 466 | 792 | 583 |
| Common shares outstanding (cover page) millions of shares | 40 | 47 | 47 | 56 | 66 | 67 |
Cash flows
CSVFiscal years (CLDX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | — | — | — | (141) | (158) | (259) |
| Stock-based compensation | 4 | 9 | 16 | 24 | 34 | 36 |
| Depreciation and amortization | 4 | 3 | 3 | 3 | 3 | 3 |
| Net cash from operating activities | (40) | (61) | (104) | (107) | (158) | (211) |
| Purchases of property and equipment | 2 | 1 | 2 | 2 | 2 | 3 |
| Net cash from investing activities | (98) | (216) | 90 | (106) | (290) | 209 |
| Proceeds from issuing common stock | 171 | 270 | — | 216 | 432 | — |
| Net cash from financing activities | 171 | 272 | 4 | 218 | 441 | 2 |
| Net change in cash | 33 | (5) | (10) | 5 | (6) | 1 |
Compare with peers
SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Celldex Therapeutics | 47 | 0 | (57)* | 78.5M | 12.5 quarters | 10-QJun 30, 2026 |
| Ani Pharmaceuticals | 360 | 266 | 57* | not reported | — | 10-QJun 30, 2026 |
| Travere Therapeutics | 124 | 225 | 98* | 96.0M | — | 10-QSep 30, 2026 |
| Innoviva | 570 | 120 | 52* | 72.2M | — | 10-QJun 30, 2026 |
| Adaptive Biotechnologies | 170 | 72 | (6.4)* | 159.6M | 53.8 quarters | 10-QJun 30, 2026 |
| Arrowhead Pharmaceuticals | 55 | 75 | (177)* | 141.3M | 9.0 quarters | 10-QJun 30, 2026 |
| Mannkind | 53 | 109 | (18)* | 321.5M | 6.0 quarters | 10-QJun 30, 2026 |
| Schrodinger | 288 | 59 | (34)* | not reported | 12.1 quarters | 10-QJun 30, 2026 |
| Spyre Therapeutics | 83 | not reported | (77)* | 95.0M | 15.7 quarters | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.